Prolonged class II MHC disparate skin allograft survival by treatment with antibodies to the chemokine Mig.
Koga
S
S
Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Kobayashi
H
H
Novick
A C
AC
Toma
H
H
Fairchild
R L
RL
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D054370:Chemokine CXCL9; D019743:Chemokines, CXC / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D036341:Intercellular Signaling Peptides and Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D016038:Skin Transplantation / Q000276:immunology* / Q000502:physiology; D013997:Time Factors; D014184:Transplantation, Homologous
D000906:Antibodies; C080810:CXCL9 protein, human; D054370:Chemokine CXCL9; D019743:Chemokines, CXC; D000949:Histocompatibility Antigens Class II; D036341:Intercellular Signaling Peptides and Proteins